APAditea Etnawati Putri

Aditea Etnawati Putri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aditea Etnawati Putri has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association between comorbidity burden and subclinical cardiac dysfunction in cancer patients prior to chemotherapy

    by Dian Paramita Kartikasari, Budi Susetio Pikir, Achmad Lefi, Tri Widiandani, Desak Gede Agung Suprabawati, Aditea Etnawati Putri, Azril Okta Ardhiansyah, Emildha Dwi Agustina

    Background: Subclinical cardiac dysfunction is a growing concern in cancer patients receiving chemotherapy. Early detection before treatment initiation is crucial to prevent overt cardiotoxicity. Objective: This study evaluates the association between comorbidity burden and subclinical cardiac dysfunction, using echocardiographic parameters, in cancer patients prior to chemotherapy. Method: This retrospective observational study analysed 110 cancer patients who underwent transthoracic echocardiography before chemotherapy. Comorbidity burden was assessed using the Charlson Comorbidity Index (CCI) and Karnofsky Performance Status (KPS). Echocardiographic evaluation included Global Longitudinal Strain (GLS), the E/e[ ] ratio (early transmitral inflow velocity to early diastolic mitral annular velocity) and left atrial volume index (LAVI). Subclinical dysfunction was defined as [ ] and/or diastolic dysfunction. Spearman’s rank correlation and multivariable linear regression were performed. Results: Abnormal GLS ([ ]) was found in 68 patients (61.8%), while 42 patients (38.2%) had normal GLS values. Higher comorbidity burden (CCI) was modestly associated with worse GLS ([ ], [ ]) and higher E/e[ ] ([ ], [ ]), whereas better functional status (Karnofsky score) correlated with more preserved GLS ([ ], [ ]). Higher age was independently associated with higher E/e[ ] ([ ], 95% CI 0.005–0.065, [ ], [ ]), whereas the association between CCI and E/e[ ] was of borderline significance ([ ], 95% CI −0.024–0.396, [ ], [ ]). Conclusion: This study showed a significant correlation between comorbidity indices and GLS as well as diastolic function parameters. This suggests that comorbidity burden and functional status are significantly associated with subclinical cardiac abnormalities before chemotherapy.

  • Existing Tubular Injury in β-Thalassemia Major Patients Receiving Iron Chelating Agents with Normal Creatinine Level in East Java, Indonesia

    by Pradana Zaky Romadhon, Ami Ashariati, Siprianus Ugroseno Yudho Bintoro, Satriyo Dwi Suryantoro, Choirina Windradi, Bagus Aulia Mahdi, Krisnina Nurul Widyastuti, Etha Dini Widiasi, Kartika Prahasanti, Aditea Etnawati Putri, et al.

    Patients suffering from thalassemia are recipients of routine transfusions leading to hemosiderosis. Taking iron chelating agents is mandatory. Several studies have shown different results regarding the occurrence of kidney complications in thalassemia patients who received iron-chelating agents. In this study, we were looking for kidney complications by examining human NAG urine/serum and NGAL urine/serum in thalassemia community in East Java community. The study was conducted cross-sectionally in the thalassemia community in East Java with a total sample of 91 patients aged 13-48 years. All thalassemia patients filled in demographic data, transfusion routines, duration of taking iron chelating agents, and length of time diagnosed with thalassemia. Laboratory tests included routine blood tests for ferritin, ureum, serum creatinine, human NAG urine or serum, and human NGAL urine or serum. Comparison tests (t-test, Mann-Whitney, and ANOVA, Kruskal-Wallis) were conducted to see if there were significant differences in the levels of human NAG urine and human NGAL urine serum based on age, sex, blood group, duration of transfusion, routine of transfusion, duration of taking iron chelating agents, and types of iron chelating drugs. Multivariate analysis was conducted to see whether some of these categories were related to abnormalities in human NAG urine or serum and human NGAL urine or serum. All 91 patients had normal creatinine values, yet some had abnormal serum NAG. There is a significant difference in urine human NAG and urine human NGAL levels at ages over 23 years (p = 0.05 and p = 0.01). Significant differences in human NGAL serum were also found in working and student patients (p = 0.028). Serum NGAL also differed in those taking deferasirox (p = 0.030) and significantly different human NGAL urine was also found in iron overload status (Ferritin >= 1000 ng.ml) (p = 0.006). There is no difference between human NAG urine/serum and human NGAL urine/serum based on sex, body mass index, blood type, hemoglobin less than 10 g/dl, routine transfusion once a month, duration of using iron chelation for more than 10 years, or splenomegaly status (splenomegaly, splenectomy, or no splenomegaly). The multivariate logistic regression results showed that age above 23 was a factor associated with abnormal urine human NAG levels (aOR = 3.79, 95% CI = 1.08-13.28). Students (aOR = 4.89, 95% CI = 1.48-16.16) with ages above 23 years (aOR = 3.69, 95% CI = 1.09-12.43) showed higher risk for an abnormal serum human NGAL levels. Patients with beta-thalassemia major exhibit noticeable tubular damage. Further research is encouraged to determine other factors behind tubular damage in the thalassemia community, particularly in Indonesia.


  • Open Access

    Examining convalescent plasma transfusion in severe COVID-19 patients, recent research highlights the significance of S-RBD antibodies and IL-10 levels

    by Dr. Sp.P.K. Aditea Etnawati Putri, Betty Agustina Tambunan, Bambang Pujo Semedi, Narazah Mohd Yusoff, Siti Salmah Bt Noordin

    Convalescent plasma (CP) may be an option for people with severe COVID-19. However, its efficiency remains unknown. A study was done to determine whether the levels of Anti-SARS-CoV-2 Spike Receptor-Binding Domain (S-RBD) antibodies and IL-10 in COVID-19 patients who had CP transfusion were related to their survival status. The observational cohort study included 40 patients with severe COVID-19 who were followed for 28 days after receiving a CP transfusion. Antibody and IL-10 levels were assessed on Day 1 before to CP transfusion and on Days 1, 2, and 7 following CP transfusion. Twenty six (65%) of the 40 patients survived. Anti-SARS-CoV-2 S-RBD antibody levels were observed to be significantly higher on Days 1, 2, and 7 following CP transfusion (p-value 0.05). Furthermore, IL-10 levels dropped significantly on Days 2 and 7 (p-value 0.05). However, neither the CT value nor the patients' survival status were linked to greater antibody levels or changes in IL-10 levels. According to the findings, CP transfusion can greatly enhance anti-SARS-CoV-2 S-RBD antibody levels while drastically decreasing IL-10 levels. These findings may have therapeutic implications for the use of CP as a COVID-19 therapy option. More research is needed to determine its efficacy in enhancing the survival rate of COVID-19 patients with severe symptoms.

  • Open Access

    Markers of Renal Complications in Beta Thalassemia Patients with Iron Overload Receiving Chelation Agent Therapy: A Systematic Review

    by Pradana Zaky Romadhon, Ami Ashariati, Siprianus Ugroseno Yudho Bintoro, Mochammad Thaha, Satriyo Dwi Suryantoro, Choirina Windradi, Bagus Aulia Mahdi, Dwiki Novendrianto, Krisnina Nurul Widiyastuti, Okla Sekar Martani, et al.

    Objective: The emerging renal complications in beta-thalassemia patients have raised the global exchange of views. Despite better survival due to blood transfusion and iron chelation therapy, the previously unrecognized renal complication remain a burden of disease affecting this population —the primary concern on how iron overload and chelation therapy correlated with renal impairment is still controversial. Early detection and diagnosis is crucial in preventing further kidney damage. Therefore, a systematic review was performed to identify markers of kidney complications in beta thalassemia patients with iron overload receiving chelation therapy. Methods: Searches of PubMed, Scopus, Science Direct, and Web of Science were conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) to identify studies of literature reporting renal outcome in β-TM patients with iron overload and receiving chelation therapy. The eligible 17 studies were obtained. Results: uNGAL/NGAL, uNAG/NAG, uKIM-1 are markers that can be used as predictor of renal tubular damage in early renal complications, while Cystatin C and uβ 2MG showed further damage at the glomerular level. Discussion and Conclusion: The renal complication in beta-thalassemia patients with iron overload receiving chelating agent therapy may progress to kidney disease. Early detection using accurate biological markers is a substantial issue that deserves further evaluation to determine prevention and management.